AbCellera Biologics (ABCL) Current Assets (2020 - 2026)

AbCellera Biologics' Current Assets history runs 7 years deep, the most recent figure standing at $664.6 million for Q1 2026.

• Quarterly Current Assets fell 13.12% year-over-year to $664.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $664.6 million (down 13.12% YoY) and the FY2025 annual result came in at $728.2 million, down 3.08% from the prior year.
• Current Assets was $664.6 million for Q1 2026 at AbCellera Biologics, down from $728.2 million in the prior quarter.
• Across five years, Current Assets topped out at $1.2 billion in Q1 2022 and bottomed at $664.6 million in Q1 2026.
• A 5-year average of $866.3 million and a median of $813.9 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets soared 32.4% — and 2023, when it decreased 19.9%.
• AbCellera Biologics' Current Assets stood at $1.0 billion in 2022, then fell by 14.97% to $872.0 million in 2023, then declined by 13.83% to $751.4 million in 2024, then fell by 3.08% to $728.2 million in 2025, then retreated by 8.74% to $664.6 million in 2026.
• Business Quant data shows ABCL's Current Assets at $664.6 million in Q1 2026, $728.2 million in Q4 2025, and $695.1 million in Q3 2025.